Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an update.
Botanix Pharmaceuticals has reported strong demand for its newly launched product, Sofdra, a topical gel for treating primary axillary hyperhidrosis. Since its launch in early 2025, Sofdra has achieved gross sales of approximately $25 million AUD, with over 16,000 prescriptions filled for more than 6,700 patients. The company is expanding its market presence by increasing the number of sales territories and investing in strategic marketing initiatives. The high refill rates and positive patient adherence suggest a strong market acceptance, positioning Botanix for continued growth in the dermatology sector.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix, specializing in the development of treatments for skin conditions. The company has received FDA approval for its lead product, Sofdra, which is a novel treatment for primary axillary hyperhidrosis, a condition characterized by excessive underarm sweating.
Average Trading Volume: 9,377,316
Technical Sentiment Signal: Hold
Current Market Cap: A$666.8M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.